CA3135309A1 - Isochromene derivatives as phosphoinositide 3-kinases inhibitors - Google Patents

Isochromene derivatives as phosphoinositide 3-kinases inhibitors Download PDF

Info

Publication number
CA3135309A1
CA3135309A1 CA3135309A CA3135309A CA3135309A1 CA 3135309 A1 CA3135309 A1 CA 3135309A1 CA 3135309 A CA3135309 A CA 3135309A CA 3135309 A CA3135309 A CA 3135309A CA 3135309 A1 CA3135309 A1 CA 3135309A1
Authority
CA
Canada
Prior art keywords
amino
methyl
pheny1
pyrimidin
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3135309A
Other languages
English (en)
French (fr)
Inventor
Matteo Biagetti
Paolo RONCHI
Claudio FIORELLI
Paolo Bruno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of CA3135309A1 publication Critical patent/CA3135309A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CA3135309A 2019-04-04 2020-03-24 Isochromene derivatives as phosphoinositide 3-kinases inhibitors Pending CA3135309A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19167245.0 2019-04-04
EP19167245 2019-04-04
PCT/EP2020/058168 WO2020200918A1 (en) 2019-04-04 2020-03-24 Isochromene derivatives as phosphoinositide 3-kinases inhibitors

Publications (1)

Publication Number Publication Date
CA3135309A1 true CA3135309A1 (en) 2020-10-08

Family

ID=66092138

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3135309A Pending CA3135309A1 (en) 2019-04-04 2020-03-24 Isochromene derivatives as phosphoinositide 3-kinases inhibitors

Country Status (26)

Country Link
US (1) US12527797B2 (enExample)
EP (1) EP3947384B1 (enExample)
JP (1) JP2022526973A (enExample)
KR (1) KR20210149077A (enExample)
CN (1) CN113874376A (enExample)
AR (1) AR118588A1 (enExample)
AU (1) AU2020252904A1 (enExample)
BR (1) BR112021019589A2 (enExample)
CA (1) CA3135309A1 (enExample)
DK (1) DK3947384T3 (enExample)
ES (1) ES2970530T3 (enExample)
FI (1) FI3947384T3 (enExample)
HR (1) HRP20240130T1 (enExample)
HU (1) HUE065052T2 (enExample)
IL (1) IL286937A (enExample)
MA (1) MA55479A (enExample)
MX (1) MX2021011979A (enExample)
MY (1) MY206575A (enExample)
PH (1) PH12021552402A1 (enExample)
PL (1) PL3947384T3 (enExample)
PT (1) PT3947384T (enExample)
SG (1) SG11202110801XA (enExample)
SI (1) SI3947384T1 (enExample)
TW (1) TW202102504A (enExample)
WO (1) WO2020200918A1 (enExample)
ZA (1) ZA202107710B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024180207A1 (en) 2023-03-02 2024-09-06 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
TWI672297B (zh) 2013-12-18 2019-09-21 義大利商吉斯藥品公司 作為磷脂肌醇-3-激酶抑制劑之異唏衍生物
ES2750791T3 (es) 2014-06-17 2020-03-27 Chiesi Farm Spa Derivados de indolizina como inhibidores de fosfoinositido 3-quinasas
US9745308B2 (en) 2014-09-12 2017-08-29 Chiesi Farmaceutici S.P.A. Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
US9968604B2 (en) 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
WO2017134053A1 (en) 2016-02-04 2017-08-10 Chiesi Farmaceutici S.P.A. Pyrazole derivatives as phosphoinositide 3-kinases inhibitors

Also Published As

Publication number Publication date
ES2970530T3 (es) 2024-05-29
MX2021011979A (es) 2021-11-03
HRP20240130T1 (hr) 2024-04-12
AU2020252904A1 (en) 2021-11-18
SG11202110801XA (en) 2021-10-28
AR118588A1 (es) 2021-10-20
ZA202107710B (en) 2025-03-26
JP2022526973A (ja) 2022-05-27
HUE065052T2 (hu) 2024-04-28
PH12021552402A1 (en) 2022-06-20
DK3947384T3 (da) 2024-01-08
EP3947384A1 (en) 2022-02-09
MY206575A (en) 2024-12-24
CN113874376A (zh) 2021-12-31
EP3947384B1 (en) 2023-11-01
WO2020200918A1 (en) 2020-10-08
FI3947384T3 (fi) 2024-01-30
US20220175784A1 (en) 2022-06-09
US12527797B2 (en) 2026-01-20
BR112021019589A2 (pt) 2021-12-07
MA55479A (fr) 2022-02-09
PT3947384T (pt) 2024-01-29
IL286937A (en) 2021-10-31
SI3947384T1 (sl) 2024-03-29
KR20210149077A (ko) 2021-12-08
PL3947384T3 (pl) 2024-03-25
TW202102504A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
US12234235B2 (en) Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
ES2866152T3 (es) Derivados de tirosina amida como inhibidores de la Rho-quinasa
TWI866258B (zh) 用於治療發炎性病症之新穎化合物及其醫藥組合物
AU2021203734A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
EP3423445B1 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
ES2755355T3 (es) Derivados de isocromeno como inhibidores de fosfoinosítido 3-quinasas
US12479826B2 (en) Pyridazinyl amino derivatives as ALK5 inhibitors
RS54761B1 (sr) Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
EP3283481B1 (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors
US11725007B2 (en) Meta tyrosine derivatives as rho-kinase inhibitors
US11332468B2 (en) Azaindole derivatives as Rho-kinase inhibitors
EP3947384B1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
EP4073073B1 (en) Thienopyrimidine derivatives as lpa receptor 2 inhibitors
EP4313972B1 (en) Indoline derivatives as ddrs inhibitors
HK40057264A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220922

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250603

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: T-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260505